Todd A. Verdoorn
Plus aucun poste en cours
Profil
Todd A.
Verdoorn was the founder of Algos Therapeutics, Inc. founded in 2003, where he held the title of Chief Operating & Scientific Officer from 2003 to 2007.
He was also the Chief Scientific Officer at DiaMedica Therapeutics, Inc. from 2016 to 2019.
Dr. Verdoorn's former positions include being the Chief Scientific Officer at Orasi Medical, Inc. from 2008 to 2011, Vice President-Neurobiology at NeuroTherapeutics Pharma, Inc. from 2011 to 2013, and Chief Scientist at Intuitive Quantitation LLC from 2013 to 2016.
He also held positions at Bristol-Myers Squibb Pharmaceutical Research Institute, Vanderbilt University, Max-Planck-Institute for Molecular Genetics, and Smart Bioscience SAS.
Dr. Verdoorn's education includes an undergraduate degree from Central College and a doctorate from The University of North Carolina at Asheville.
Anciens postes connus de Todd A. Verdoorn
| Sociétés | Poste | Fin |
|---|---|---|
| DIAMEDICA THERAPEUTICS INC. | Directeur Technique/Scientifique/R&D | 15/11/2019 |
| Intuitive Quantitation LLC | Corporate Officer/Principal | 01/12/2016 |
NeuroTherapeutics Pharma, Inc.
 NeuroTherapeutics Pharma, Inc. Pharmaceuticals: MajorHealth Technology NeuroTherapeutics Pharma, Inc. is a biopharmaceutical company focused on developing therapies for diseases associated with central nervous system hyper-excitability. It is developing compounds that decrease or eliminate aberrant excitatory discharges by working through a new mechanism of action. The firm's proprietary molecules target a novel molecular site that will create a pipeline of potential new treatments for multiple CNS disorders. The company's lead compound, NTP-2014, has exhibited excellent efficacy results in multiple preclinical models of epilepsy, acute and neuropathic pain. NeuroTherapeutics Pharma was founded in 2006 and is headquartered in Chicago, IL. | Corporate Officer/Principal | 01/05/2013 |
Orasi Medical, Inc.
 Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | Directeur Technique/Scientifique/R&D | 01/08/2011 |
| Smart Bioscience SAS | Directeur Technique/Scientifique/R&D | 01/01/2008 |
Formation de Todd A. Verdoorn
| Central College | Undergraduate Degree |
| The University of North Carolina at Asheville | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DIAMEDICA THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Orasi Medical, Inc.
Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | Health Services |
| Bristol-Myers Squibb Pharmaceutical Research Institute | |
NeuroTherapeutics Pharma, Inc.
NeuroTherapeutics Pharma, Inc. Pharmaceuticals: MajorHealth Technology NeuroTherapeutics Pharma, Inc. is a biopharmaceutical company focused on developing therapies for diseases associated with central nervous system hyper-excitability. It is developing compounds that decrease or eliminate aberrant excitatory discharges by working through a new mechanism of action. The firm's proprietary molecules target a novel molecular site that will create a pipeline of potential new treatments for multiple CNS disorders. The company's lead compound, NTP-2014, has exhibited excellent efficacy results in multiple preclinical models of epilepsy, acute and neuropathic pain. NeuroTherapeutics Pharma was founded in 2006 and is headquartered in Chicago, IL. | Health Technology |
Algos Therapeutics, Inc.
 Algos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Algos PreClinical Services, Inc. engages in preclinical pain drug development. It specializes in preclinical in vivo pain research and program consulting. The company was founded by Susanne C. Dvorak and Todd C. Verdoorn in 2003 and is headquartered in Roseville, MN. | Health Technology |
| Intuitive Quantitation LLC | |
| Smart Bioscience SAS |